123 related articles for article (PubMed ID: 30844374)
1. Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio.
Muthuraman A; Nafisa K; Sowmya MS; Arpitha BM; Choedon N; Sandy CD; Rishitha N; Johurul I
Life Sci; 2019 Apr; 222():133-139. PubMed ID: 30844374
[TBL] [Abstract][Full Text] [Related]
2. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic evaluation of solid lipid nanoparticle of quercetin in pentylenetetrazole induced cognitive impairment of zebrafish.
Rishitha N; Muthuraman A
Life Sci; 2018 Apr; 199():80-87. PubMed ID: 29522770
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Vizza CD; Fedele F; Pezzuto B; Rubin LJ
Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of ambrisentan.
Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
[TBL] [Abstract][Full Text] [Related]
6. Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis.
Sumida H; Asano Y; Hatano M; Aozasa N; Toyama T; Akamata K; Miyazaki M; Taniguchi T; Takahashi T; Ichimura Y; Noda S; Kuwano Y; Yanaba K; Sato S
Mod Rheumatol; 2016; 26(3):454-7. PubMed ID: 24593173
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan and its role in the management of pulmonary arterial hypertension.
Macintyre IM; Dhaun N; Goddard J; Webb DJ
Drugs Today (Barc); 2008 Dec; 44(12):875-85. PubMed ID: 19198697
[TBL] [Abstract][Full Text] [Related]
8. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.
Halank M; Knudsen L; Seyfarth HJ; Ewert R; Wiedemann B; Kolditz M; Höffken G; Hoeper MM
Z Gastroenterol; 2011 Sep; 49(9):1258-62. PubMed ID: 21887662
[TBL] [Abstract][Full Text] [Related]
9. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
10. Ambrisentan.
Croxtall JD; Keam SJ
Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
[TBL] [Abstract][Full Text] [Related]
11. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice.
Kasztan M; Fox BM; Speed JS; De Miguel C; Gohar EY; Townes TM; Kutlar A; Pollock JS; Pollock DM
J Am Soc Nephrol; 2017 Aug; 28(8):2443-2458. PubMed ID: 28348063
[TBL] [Abstract][Full Text] [Related]
13. Effects of ambrisentan in a patient affected by combined pulmonary fibrosis and emphysema and by severe pulmonary hypertension: clinical, functional, and biomolecular findings.
Roccia F; Campolo B; Gallelli L; Spaccarotella C; Mongiardo A; Falcone D; Savino R; Pelaia G; Indolfi C; Maselli R
Clin Drug Investig; 2013 Jun; 33(6):451-7. PubMed ID: 23605508
[TBL] [Abstract][Full Text] [Related]
14. Ambrisentan.
Frampton JE
Am J Cardiovasc Drugs; 2011 Aug; 11(4):215-26. PubMed ID: 21623643
[TBL] [Abstract][Full Text] [Related]
15. Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis.
Kappes L; Amer RL; Sommerlatte S; Bashir G; Plattfaut C; Gieseler F; Gemoll T; Busch H; Altahrawi A; Al-Sbiei A; Haneefa SM; Arafat K; Schimke LF; Khawanky NE; Schulze-Forster K; Heidecke H; Kerstein-Staehle A; Marschner G; Pitann S; Ochs HD; Mueller A; Attoub S; Fernandez-Cabezudo MJ; Riemekasten G; Al-Ramadi BK; Cabral-Marques O
Sci Rep; 2020 Sep; 10(1):15931. PubMed ID: 32985601
[TBL] [Abstract][Full Text] [Related]
16. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
Rubin LJ
Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
[TBL] [Abstract][Full Text] [Related]
18. Ambrisentan, a non-peptide endothelin receptor antagonist.
Vatter H; Seifert V
Cardiovasc Drug Rev; 2006; 24(1):63-76. PubMed ID: 16939634
[TBL] [Abstract][Full Text] [Related]
19. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.
Peacock AJ; Zamboni W; Vizza CD
Curr Med Res Opin; 2015; 31(9):1793-807. PubMed ID: 26196225
[TBL] [Abstract][Full Text] [Related]
20. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Raghu G; Behr J; Brown KK; Egan JJ; Kawut SM; Flaherty KR; Martinez FJ; Nathan SD; Wells AU; Collard HR; Costabel U; Richeldi L; de Andrade J; Khalil N; Morrison LD; Lederer DJ; Shao L; Li X; Pedersen PS; Montgomery AB; Chien JW; O'Riordan TG;
Ann Intern Med; 2013 May; 158(9):641-9. PubMed ID: 23648946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
